Covid 19 Research using Clinical Trials (Home Page)
Report for D006470: Hemorrhage NIH
(Synonyms: Hemorr, Hemorrh, Hemorrhage)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (6)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug713 | Colorectal resection Wiki | 0.50 |
| drug340 | BI 1569912 Wiki | 0.50 |
| drug2884 | The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: Wiki | 0.50 |
| drug2766 | Supraflex Cruz 60 Micron Wiki | 0.50 |
| drug2998 | Ultimaster Tansei 80 Micron Wiki | 0.50 |
| drug2122 | Placebo Wiki | 0.03 |
Correlated MeSH Terms (27)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D001997 | Bronchopulmonary Dysplasia NIH | 0.50 |
| D008595 | Menorrhagia NIH | 0.50 |
| D006929 | Hyperaldosteronism NIH | 0.50 |
| D013226 | Status Epilepticus NIH | 0.50 |
| D002543 | Cerebral Hemorrhage NIH | 0.50 |
| D054559 | Hyperphosphatemia NIH | 0.50 |
| D004314 | Down Syndrome NIH | 0.50 |
| D013345 | Subarachnoid Hemorrhage NIH | 0.50 |
| D000309 | Adrenal Insufficiency NIH | 0.50 |
| D007008 | Hypokalemia NIH | 0.50 |
| D009080 | Mucocutaneous Lymph Node Syndrome NIH | 0.35 |
| D014552 | Urinary Tract Infections NIH | 0.35 |
| D001289 | Attention Deficit Disorder with Hyperactivity NIH | 0.25 |
| D000070642 | Brain Injuries, Traumatic NIH | 0.19 |
| D006331 | Heart Diseases NIH | 0.18 |
| D001930 | Brain Injuries, NIH | 0.17 |
| D020521 | Stroke NIH | 0.14 |
| D020141 | Hemostatic Disorders NIH | 0.13 |
| D001778 | Blood Coagulation Disorders NIH | 0.13 |
| D006973 | Hypertension NIH | 0.13 |
| D014947 | Wounds and Injuries NIH | 0.10 |
| D004194 | Disease NIH | 0.09 |
| D013577 | Syndrome NIH | 0.05 |
| D003141 | Communicable Diseases NIH | 0.04 |
| D007239 | Infection NIH | 0.03 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.02 |
| D018352 | Coronavirus Infections NIH | 0.02 |
Correlated HPO Terms (12)
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0002905 | Hyperphosphatemia HPO | 0.50 |
| HP:0002900 | Hypokalemia HPO | 0.50 |
| HP:0002133 | Status epilepticus HPO | 0.50 |
| HP:0000846 | Adrenal insufficiency HPO | 0.50 |
| HP:0002138 | Subarachnoid hemorrhage HPO | 0.50 |
| HP:0000132 | Menorrhagia HPO | 0.50 |
| HP:0001342 | Cerebral hemorrhage HPO | 0.50 |
| HP:0000859 | Hyperaldosteronism HPO | 0.50 |
| HP:0007018 | Attention deficit hyperactivity disorder HPO | 0.25 |
| HP:0001297 | Stroke HPO | 0.14 |
| HP:0001928 | Abnormality of coagulation HPO | 0.13 |
| HP:0000822 | Hypertension HPO | 0.13 |
There are 4 clinical trials
Clinical Trials
1 Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs
The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.
NCT04278404 Coronavirus Infection (COVID-19) Pulmonary Arterial Hypertension Urinary Tract Infections in Children Hypertension Pain Hyperphosphatemia Primary Hyperaldosteronism Edema Hypokalemia Heart Failure Hemophilia Menorrhagia In Insomnia Pneumonia Skin Infection Arrythmia Asthma in Children Bronchopulmonary Dysplasia Adrenal Insufficiency Fibrinolysis; Hemorrhage Attention Deficit Hyperactivity Disorder Multisystem Inflammatory Syndrome in Children (MIS-C) Kawasaki Disease Coagulation Disorder Down Syndrome Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: MeSH:Infection Communicable Diseases Urinary Tract Infections Coronavirus Infections Severe Acute Respiratory Syndrome Bronchopulmonary Dysplasia Down Syndrome Menorrhagia Hypertension Hemostatic Disorders Mucocutaneous Lymph Node Syndrome Blood Coagulation Disorders Hyperphosphatemia Hypokalemia Adrenal Insufficiency Hyperaldosteronism Disease Syndrome Hemorrhage Attention Deficit Disorder with Hyperactivity
HPO:Abnormality of coagulation Abnormality of the coagulation cascade Adrenal insufficiency Attention deficit hyperactivity disorder Hyperaldosteronism Hyperphosphatemia Hypertension Hypokalemia Menorrhagia Primary hyperaldosteronism
Primary Outcomes
Measure: Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.
Measure: Volume of distribution (V) or apparent oral volume of distribution (V/F) as measured by PK sampling Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.
Measure: Elimination rate constant (ke) as measured by PK sampling Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.
Measure: Half-life (t1/2) as measured by PK sampling Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.
Measure: Absorption rate constant (ka) as measured by PK sampling Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.
Measure: AUC (area under the curve) as measured by PK sampling Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.
Measure: Maximum concentration (Cmax) as measured by PK sampling Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.
Measure: Time to achieve maximum concentration (Tmax) as measured by PK sampling Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.
2 Prevalence of Severe Bleeding in COVID-19 Patients Treated With Higher Than Recommended Thromboprophylaxis Doses (BLEEDING Study)
Primary Outcomes
Measure: Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.Measure: Volume of distribution (V) or apparent oral volume of distribution (V/F) as measured by PK sampling Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.
Measure: Elimination rate constant (ke) as measured by PK sampling Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.
Measure: Half-life (t1/2) as measured by PK sampling Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.
Measure: Absorption rate constant (ka) as measured by PK sampling Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.
Measure: AUC (area under the curve) as measured by PK sampling Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.
Measure: Maximum concentration (Cmax) as measured by PK sampling Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.
Measure: Time to achieve maximum concentration (Tmax) as measured by PK sampling Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.
The main objectives are: - To establish the prevalence of major bleeding in patients treated with higher than recommended thromboprophylaxis doses. - To identify variables associated to higher risk of bleeding.
NCT04380779 COVID-19 MeSH:Hemorrhage
Primary Outcomes
Description: Study endpoints are clinically recognized (and objectively confirmed) major and minor bleeding complications, and death.
Measure: Bleeding events and complications Time: 30 days3 Severe Neurologic Injury Outcomes During COVID-19 Crisis
A prospective cohort minimal risk study to determine the impact of the COVID-19 crisis on outcomes of neurologically injured ICU patients.
NCT04496076 Sars-CoV2 Severe Neurologic Injury Ischemic Stroke Hemorrhagic Stroke Intracerebral Hemorrhage Subarachnoid Hemorrhage Traumatic Brain Injury Status Epilepticus MeSH:Stroke Brain Injuries Brain Injuries, Traumatic Subarachnoid Hemorrhage Cerebral Hemorrhage Status Epilepticus Hemorrhage Wounds and Injuries
HPO:Cerebral hemorrhage Status epilepticus Stroke Subarachnoid hemorrhage
Primary Outcomes
Measure: In-hospital Mortality Time: At hospital discharge, approximately 1 month
Measure: 30-day mortality Time: 30 days post-hospital discharge
Secondary Outcomes
Description: Care treatment such as ventilator use, intubation, and/or tracheostomy
Measure: Limitations of patient care- Frequency of care not being provided Time: During In-hospital course, up to 1 month
Measure: Limitations of patient care- Conversion of DNR/DNI/CMO status Time: During In-hospital course, up to 1 month
4 Comparison of the Supraflex Cruz 60 Micron Stent Strut Versus the Ultimaster Tansei 80 Micron Stent Strut in High Bleeding Risk PCI Population
Primary Outcomes
Measure: In-hospital Mortality Time: At hospital discharge, approximately 1 monthMeasure: 30-day mortality Time: 30 days post-hospital discharge
Secondary Outcomes
Description: Care treatment such as ventilator use, intubation, and/or tracheostomy
Measure: Limitations of patient care- Frequency of care not being provided Time: During In-hospital course, up to 1 monthMeasure: Limitations of patient care- Conversion of DNR/DNI/CMO status Time: During In-hospital course, up to 1 month
The study compares the outcome of the ultrathin stent strut Supraflex Cruz stent to the thin stent strut Ultimaster Tansei stent in a PCI population at high risk for bleeding (HBR).
NCT04500912 Cardiac D Cardiac Disease PCI High Bleeding Risk Device: Supraflex Cruz 60 Micron Device: Ultimaster Tansei 80 Micron MeSH:Heart Diseases Hemorrhage
Primary Outcomes
Description: The primary endpoint Net Adverse Clinical Endpoints (NACE) defined as a composite of cardiovascular death, myocardial infarction, target vessel revascularization, stroke and bleeding events defined as BARC 3 or 5 at 12 months follow-up after the index PCI.
Measure: Net Adverse Clinical Endpoints (NACE) Time: 1 yearSecondary Outcomes
Description: Major adverse cardiac and cerebral events (MACCE) defined as a composite of cardiac death, myocardial infarction, target vessel revascularization and stroke
Measure: Major adverse cardiac and cerebral events (MACCE) Time: 1 yearDescription: Major or clinically relevant non-major bleeding (MCB) defined as a composite of type 2, 3 and 5 BARC bleeding events
Measure: Major or clinically relevant non-major bleeding (MCB) Time: 1 yearDescription: Target Lesion Failure (TLF) is defined as cardiac death, myocardial infarction attributed to the target vessel and clinically indicated target lesion revascularization
Measure: Target Lesion Failure (TLF) Time: 1 yearDescription: Target Vessel Failure (TVF) is defined as cardiac death, myocardial infarction attributed to the target vessel and clinically indicated target vessel revascularization
Measure: Target vessel failure (TVF) Time: 1 yearDescription: The composite endpoint of cardiovascular death, myocardial infarction and stroke
Measure: The composite of cardiovascular death, myocardial infarction and stroke Time: 1 yearDescription: The composite of cardiovascular death, myocardial infarction, stroke and major bleed according to BARC 3 and 5
Measure: The composite of cardiovascular death, myocardial infarction, stroke and major bleed BARC 3 and 5 Time: 1 yearDescription: Stent thrombosis according to the ARC definitions
Measure: Stent thrombosis Time: 1 yearDescription: Myocardial infarction.
Measure: Myocardial infarction Time: 1 yearDescription: Urgent target vessel revascularization.
Measure: Urgent target vessel revascularization Time: 1 yearDescription: Non-target vessel revascularization.
Measure: Non-target vessel revascularization Time: 1 yearDescription: Clinically indicated target vessel revascularization.
Measure: Clinically indicated target vessel revascularization Time: 1 yearDescription: Bleeding events
Measure: Bleeding events Time: 1 yearDescription: Transfusion rates both in patients with and/or without clinically detected over bleeding
Measure: Transfusion rates Time: 1 yearDescription: Event rates according to the PRECISE-DAPT score
Measure: Event rates according to the PRECISE-DAPT Time: 1 yearDescription: Procedural success.
Measure: Procedural success Time: 1 yearDescription: Device success.
Measure: Device success Time: 1 year